Aster DM Healthcare Limited has scheduled analyst and institutional investor meets in Hyderabad and Bengaluru for June 10 and June 11, 2026. The company will participate in these sessions through its representatives as part of meetings organized by Macquarie. The disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The upcoming meetings will include investor group interactions. The company stated that no unpublished price sensitive information would be shared during these events. The schedule is subject to change based on exigencies involving investors, analysts, or the company.

The details of the newly scheduled events are as follows:

The intimation was signed by Hemish Purushottam, Company Secretary and Compliance Officer of Aster DM Healthcare Limited.

Aster DM Healthcare reported revenue of ₹4,643 crore for the financial year ended March 31, 2026, representing a 12% increase from the previous year. Operating EBITDA for the period stood at ₹947 crore, with margins expanding to 20.4%. The company’s board disclosed these figures in an investor presentation filed on June 03, 2026, highlighting steady growth driven by its core hospital performance and improving traction in other business units.

The company’s net profit after tax for FY26 was ₹464 crore, compared to ₹356 crore in the previous year. Normalised profit after tax, which excludes exceptional items such as merger-related costs and CSR expenses, was ₹451 crore for FY26. For the quarter ended March 31, 2026, revenue from operations was ₹1,182 crore, while operating EBITDA was ₹244 crore.

Aster DM Healthcare provided a significant update regarding its proposed merger with Blackstone-backed Quality Care. The merger proposal received overwhelming shareholder approval, with 96.68% of total votes cast in favor. The transaction is expected to be completed in Q1 FY27. The merger aims to create one of the top three hospital chains in India by revenue and bed capacity, combining a network of 10,623 beds across 28 cities.

The proforma financials for the merged entity for FY26 indicate combined revenues of ₹9,273 crore and an operating EBITDA of ₹2,013 crore, implying a margin of 21.7%. The strategic rationale for the merger includes achieving scale across South and Central India, realizing synergies in procurement and supply chain, and diversifying geographically with low overlap in city presence.

Financial Performance Summary

Operational Metrics

The company’s bed capacity increased to 5,449 in FY26 from 5,159 in the previous year. Occupancy levels stood at 61% for the year, while the average revenue per occupied bed (ARPOB) rose to ₹51,800. The company noted that its mature hospitals, operational for over seven years, contributed significantly to profitability with an operating EBITDA margin of 25.4%.

Merger Synergies

Management outlined multiple avenues for synergies post-merger, including the rationalization of procurement spends, optimization of corporate functions, and enhanced revenue potential from international patients. The merged entity plans to add 4,445 beds in the coming years, taking the total bed capacity to 15,068 beds, with a majority of the expansion being brownfield projects.